Dr. Andre Terzic is Professor of Medicine and Pharmacology at Mayo Clinic, where he holds the Marriott Professorship in Cardiovascular Research and serves as Director, Marriott Heart Disease Research Program; Director, NIH "Cardiovasology" Program; Co-Director, Kogod Program on Aging; and is Associate Director for Research. The priority of his multidisciplinary program is in deciphering pathways of stress tolerance, and identifying the genetic basis of maladaptation in human disease. This work has evolved on the principle of metabolomic networks applied to the pathogenetics of dilated cardiomyopathy and atrial fibrillation. This integrative research has led to the discovery of the role for metabolic sensors in decoding energetic distress. Failure in metabolic decoding, due to heritable genetic mutations in KATP channel subunits or abnormal signal transmission, is identified as a risk factor for cardiac disease. The promise that lies ahead is in the translation of principles of stress maladaptation, tested so far in discrete patient cohorts, into broader diagnostic and therapeutic screens applied to the population. The ability to early detect for each individual the defining genetic basis of disease risk and to treat by targeted repair deficits in diagnosed stress intolerance provides an opportunity to advance cardiovascular medicine. Dr. Terzic is the recipient of numerous national and international awards, and is Past President of the American Society for Clinical Pharmacology and Therapeutics.